Fred R. Hirsch
@fred_hirsch
I am Executive Director at the Center for Thoracic Oncology at Mount Sinai Hospital , NYC and Professor of Medicine at Icahn Medical School at Mount Sinai, NY
Great discussions of gaps in lung cancer research in Huntington Beach, California!
Great to see colleagues and learn at a lung cancer meeting in New Orleans!
our #lungcancer session at MECC New Orleans 2025 with @drgandara @IASLC Karen Kelly @lungoncdoc @JuliaRotow Paul Bunn Subramanian @fred_hirsch @EdgardoSantosMD Megan Daly Erminia Mazarelli #lcsm @mecmededucation
Here, Tuminello et al. predict that identifying malignant nodules in imaging ordered for other clinical reasons can help decrease the burden of NSCLC, especially in pts who do not qualify for LDCT screening. bit.ly/41qnPHD
Calles et al. evaluated lurbinectedin + pembrolizumab in relapsed #SCLC pts without prior immunotherapy. The combination showed promising efficacy, especially in platinum-sensitive pts. Read more: bit.ly/3Qp3xYl #LCSM @Tony_Calles
Proud to be a part of this significant publication just published in Nature Medicine.
Approval of TROP 2 ADC in EGFR+ NSCLC previously treated with EGFR TKI(s).
Great “Best of ASCO 25” arranged by the New York Lung Cancer Foundation. Here Dr. Josh Sabari from NYU summarizing KRAS therapy!
High productivity in the NIH Lung SPORE program over the last 5 years.
Great meeting with BioNTech leadership at Mount Sinai last week and great meeting the CMO Dr. Özlem Türecı, who was pivotal in the development of COVID 19 vaccine! Thanks to Dr. Miriam Merad for organizing.
Great results in small cell lung cancer with Tarlatamab as 2 line therapy. Most likely new standard of care with manageable toxicity !
At ASCO: Olomorasib plus Pembrolizumab with high response in 1. Line therapy for NSCLC KRAS G12 C patients.
Do we have a future AI based bio marker for TROP 2? Validation needed!
Encouraging results for chemo free regimen of adagrasib plus pembrolizumab in first line for pts with KRAS G12C NSCLC .
Very nice retirement party for a giant in lung cancer, Dr. Chandra Belani at ASCO in Chicago.
